Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -278.89% is 24% below its 1-year average of -224.99%, around the middle of its 1-year range (-632.98%–-56.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.38% above its 12-month average of -288.64%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -278.89%.
RETURN ON EQUITY (ROE)
-278.89%
RETURN ON EQUITY (ROE) AVG TTM
-288.64%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.38%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 681 covered companies
CURRENT VS SECTOR MEDIAN
-584.39%
vs the sector median at left
eXoZymes, Inc.
Market Cap
$51.42M
Return on Equity (ROE)
-278.89%
TTM Avg
-288.64%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.33M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$51.38M
Return on Equity (ROE)
-76.82%
TTM Avg
-798.41%
3Y Avg
-485.96%
5Y Avg
-324.45%
Market Cap
$51.91M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$51.61M
Return on Equity (ROE)
N/A
TTM Avg
-24.59%
3Y Avg
-14.57%
5Y Avg
93.61%
Market Cap
$50.66M
Return on Equity (ROE)
N/A
TTM Avg
-206.96%
3Y Avg
-221.50%
5Y Avg
-349.91%
Market Cap
$50.54M
Return on Equity (ROE)
N/A
TTM Avg
296.81%
3Y Avg
-175.08%
5Y Avg
-1071.79%
Market Cap
$50.45M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$50.08M
Return on Equity (ROE)
-23.70%
TTM Avg
-170.56%
3Y Avg
-190.10%
5Y Avg
-146.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.42M | -278.89% | -288.64% | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -708.48% | 156.13% | 510.26% | 342.91% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.38M | -76.82% | -798.41% | -485.96% | -324.45% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $51.91M | -36114.03% | -31.09% | -15.54% | -12.44% |
| biote Corp. (BTMD)vs › | $51.61M | N/A | -24.59% | -14.57% | 93.61% |
| Celularity Inc. (CELU)vs › | $50.66M | N/A | -206.96% | -221.50% | -349.91% |
| Clene Inc. (CLNN)vs › | $50.54M | N/A | 296.81% | -175.08% | -1071.79% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.45M | N/A | 31.64% | 119.26% | -26.51% |
| Microbot Medical Inc. (MBOT)vs › | $50.08M | -23.70% | -170.56% | -190.10% | -146.13% |
| INmune Bio, Inc. (INMB)vs › | $50.51M | -90.44% | -163.19% | -112.62% | -86.58% |
ROE
-278.9%
ROA
-127.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -278.89% |
| 2026-03-31 | -632.98% |
| 2025-12-31 | -269.59% |
| 2025-09-30 | -155.17% |
| 2025-06-30 | -106.54% |
| 2025-03-31 | -75.54% |
| 2024-12-31 | -56.25% |
